PrimeGene (Beijing) Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 88

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 9

PrimeGene (Beijing) General Information

Description

Developer and provider of localized targeted therapies, designed for the treatment of chronic inflammatory diseases. The company focuses on new drug discovery, R&D and commercialization featuring immune/inflammatory diseases and external use, providing new drugs for skin, ophthalmology, rhinology and respiratory system.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor, Building B, Chongxin Building
  • No. 13 Hangfeng Road, Fengtai District
  • Beijing, 100070
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3rd Floor, Building B, Chongxin Building
  • No. 13 Hangfeng Road, Fengtai District
  • Beijing, 100070
  • China
+86 010

PrimeGene (Beijing) Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PrimeGene (Beijing) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. IPO 21-Jan-2026 Announced Generating Revenue
7. Later Stage VC (Series B) 02-Jan-2025 Completed Generating Revenue
6. Later Stage VC 16-May-2024 Completed Generating Revenue
5. Later Stage VC 25-Dec-2023 Completed Clinical Trials - General
4. IPO 07-Dec-2022 Completed Clinical Trials - General
3. Later Stage VC 31-Aug-2022 Completed Clinical Trials - General
2. Secondary Transaction - Private 20-May-2021 $3.09M $23.2M Completed Clinical Trials - General
1. Early Stage VC (Series A) 20-May-2021 $23.2M $23.2M Completed Clinical Trials - General
To view PrimeGene (Beijing)’s complete valuation and funding history, request access »

PrimeGene (Beijing) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ordinary
ordinary
ordinary 16,666,666 $1.24 $1.24 1x $1.24 17.35%
ordinary 16,666,666 $1.24 $1.24 1x $1.24 17.35%
To view PrimeGene (Beijing)’s complete cap table history, request access »

PrimeGene (Beijing) Patents

PrimeGene (Beijing) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026208967-A1 Mas-related g-protein coupled receptor member x2 antagonist and use thereof Pending 03-Apr-2025
WO-2026026866-A1 Macrocyclic compound as tyk2 inhibitor and pharmaceutical composition thereof Pending 02-Aug-2024
WO-2025256614-A1 Inhibitor for promoting collagen expression Pending 14-Jun-2024
WO-2025256631-A1 Jak inhibitor for treatment of allergic rhinitis Pending 14-Jun-2024
WO-2025256637-A1 Tyrosine kinase inhibitor nasal spray Pending 14-Jun-2024
To view PrimeGene (Beijing)’s complete patent history, request access »

PrimeGene (Beijing) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PrimeGene (Beijing) Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing E-town International Industrial Investment Management Government Minority
Capital Science and Technology Development Group Venture Capital Minority
Tech Intelligence Capital Growth/Expansion Minority
Beijing State-owned Capital Operation and Management Government Minority
Sunland Fund Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

PrimeGene (Beijing) FAQs

  • When was PrimeGene (Beijing) founded?

    PrimeGene (Beijing) was founded in 2016.

  • Where is PrimeGene (Beijing) headquartered?

    PrimeGene (Beijing) is headquartered in Beijing, China.

  • What is the size of PrimeGene (Beijing)?

    PrimeGene (Beijing) has 88 total employees.

  • What industry is PrimeGene (Beijing) in?

    PrimeGene (Beijing)’s primary industry is Drug Discovery.

  • Is PrimeGene (Beijing) a private or public company?

    PrimeGene (Beijing) is a Private company.

  • What is PrimeGene (Beijing)’s current revenue?

    The current revenue for PrimeGene (Beijing) is .

  • How much funding has PrimeGene (Beijing) raised over time?

    PrimeGene (Beijing) has raised $85.6M.

  • Who are PrimeGene (Beijing)’s investors?

    Beijing E-town International Industrial Investment Management, Capital Science and Technology Development Group, Tech Intelligence Capital, Beijing State-owned Capital Operation and Management, and Sunland Fund are 5 of 9 investors who have invested in PrimeGene (Beijing).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process